Author Archive: Celia Economides

Celia was a Manager of Investor Relations & Business Development at BIO.

Latest Posts

Perspectives on today’s IPO candidates

Some speculation is coming back into the sector but most movement in public markets is specialist driven, not generalist driven. What will it take to get the generalist investors in? Unfortunately, most IPO stocks since 2005 have underperformed and have left a bad taste in the mouths of generalists. This has left generalists believing they cannot just come into the sector and purchase a basket of young biotechs. Example of a successful IPO: Targacept filed Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Positive results for Logical Therapeutics’ LT-NS001 vs. Naproxen clinical study

Logical Therapeutics, Inc. announced positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Trubion reports positive data from Phase 2B TRU-015 study

Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA. Trubion’s President and CEO, Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Rexahn reports Phase IIa data for Serdaxin

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) announced top-line results from a Phase IIa clinical study of SerdaxinTM, its major depressive disorder (MDD) drug candidate. The randomized, double blind, placebo controlled and dose ranging study enrolled 77 patients and was conducted at multiple U.S. sites to assess Serdaxin’s safety and preliminary efficacy. The study showed that patients ages 18-65 with MDD exhibited clinically meaningful improvement over baseline in symptoms of depression as measured by the Montgomery-Asberg Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Inovio begins HIV clinical trial of DNA vaccine

Inovio Biomedical Corporation (NYSE Amex: INO) and the HIV Vaccine Trials Network (HVTN) initiated a phase I clinical study of Inovio’s PENNVAX™-B preventive DNA vaccine delivered using electroporation technology. The multi-center study will be conducted at several HVTN clinical sites under a protocol designated HVTN-080. The study will enroll healthy volunteers to assess the safety of and immune responses to this DNA-based vaccine delivered via in vivo electroporation. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,